Exact Mass: 652.3459

Hernandezine

C39H44N2O7 (652.3148)

Hernandezine is a member of isoquinolines and a bisbenzylisoquinoline alkaloid. Hernandezine is a natural product found in Thalictrum delavayi, Thalictrum fendleri, and other organisms with data available. Origin: Plant; SubCategory_DNP: Isoquinoline alkaloids, Benzylisoquinoline alkaloids

Metocurine

C40H48N2O6+2 (652.3512)

D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

Anhwiedelphinine

C35H44N2O10 (652.2996)

Gnididilatin

C37H48O10 (652.3247)

Thalidasine

C39H44N2O7 (652.3148)

Metocurine

C40H48N2O6 (652.3512)

Metocurine is only found in individuals that have used or taken this drug. It is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.(PMID: 9915319)Metocurine antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

Uzarigenin 3-[xylosyl-(1->2)-rhamnoside]

C34H52O12 (652.3459)

Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is found in fruits. Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is a constituent of Tamarindus indica (tamarind) Constituent of Tamarindus indica (tamarind). Uzarigenin 3-[xylosyl-(1->2)-rhamnoside] is found in fruits.

n-[2(r)-Hydroxy-1(s)-indanyl]-2(r)-phenylmethyl-4(s)-hydroxy-5-[4-[2-benzofuranylmethyl]-2(s)-[tert-butylaminocarbonyl]-piperazinyl]-pentaneamide

C39H48N4O5 (652.3625)

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C35H57O9P (652.374)

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 4-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

C35H57O9P (652.374)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0), in particular, consists of one chain of one 4-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C35H57O9P (652.374)

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 7-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

C35H57O9P (652.374)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0), in particular, consists of one chain of one 7-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C35H57O9P (652.374)

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

C35H57O9P (652.374)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0), in particular, consists of one chain of one 14-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C35H57O9P (652.374)

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-hydroxy-docosahexaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

C35H57O9P (652.374)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0), in particular, consists of one chain of one 17-hydroxy-docosahexaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C35H57O9P (652.374)

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16,17-epoxy-docosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

C35H57O9P (652.374)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0), in particular, consists of one chain of one 16,17-epoxy-docosapentaenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Thalrugosaminine

C39H44N2O7 (652.3148)

Thalrugosaminine is a natural product found in Thalictrum foetidum with data available.

Herveline B

C39H44N2O7 (652.3148)

Thalifaramine

C39H44N2O7 (652.3148)

Hydroxymycotrienin B

C36H48N2O9 (652.336)

Withanoside III

C34H52O12 (652.3459)

Longithorol B

C42H52O6 (652.3764)

Herveline A

C39H44N2O7 (652.3148)

Hydroxymycotrienin A

C36H48N2O9 (652.336)

Cherimolacyclopeptide D

C29H48N8O9 (652.3544)

C38H53BrO4

C38H53BrO4 (652.3127)

C35H56O11

C35H56O11 (652.3822)

genkwanine C

C37H48O10 (652.3247)

(-)-calafatine|Calafatin|calafatine|ent-6,7,10,12,6-pentamethoxy-2,2-dimethyl-berbamane

C39H44N2O7 (652.3148)

ohchinolal C

C37H48O10 (652.3247)

6,7,12,6,8-pentamethoxy-2,2-dimethyl-(1xiH,1xiH)-berbamane|Hernandezin

C39H44N2O7 (652.3148)

C33H44N6O8

C33H44N6O8 (652.322)

latrunculinoside B

C34H49ClO10 (652.3014)

Thaliracebine

C39H44N2O7 (652.3148)

petuniasterone C 7,22-dinicotinate

C40H48N2O6 (652.3512)

C34H49ClO10

C34H49ClO10 (652.3014)

12??,21-Dihydroxycimigenol 3-O-??-L-arabinopyranoside

C35H56O11 (652.3822)

Myrtucommulone A

C38H52O9 (652.3611)

effusin A

C40H48N2O6 (652.3512)

(3beta,6beta,12beta,23S,24R,25S)-16,23:23,26-diepoxy-6,12,24,25-tetrahydroxy-9,19-cycloart-3-O-beta-D-xylopyranoside|yunnanterpene F

C35H56O11 (652.3822)

paradrymonoside

C35H56O11 (652.3822)

C38H52O9

C38H52O9 (652.3611)

THaliracebin

C39H44N2O7 (652.3148)

genkwanine E

C37H48O10 (652.3247)

16-demethoxymethyllycaconitine|1alpha,6beta,14alpha-trimethoxy-7,8-dihydroxy-18-(2-methyl)succinylanthranoyloxyaconane

C36H48N2O9 (652.336)

1beta,2alpha,3beta,19alpha,23-pentahydroxyurs-12-en-28-oic acid-28-O-beta-D-xylopyranoside

C35H56O11 (652.3822)

Thalifaboramine

C39H44N2O7 (652.3148)

30,30-dichlorocylindrocyclophane A|cylindrocyclophane A2

C36H54Cl2O6 (652.3297)

Pisopowine

C40H48N2O6 (652.3512)

Thalrugosaminin

C39H44N2O7 (652.3148)

Nostocyclophane D

C36H54Cl2O6 (652.3297)

wikstroelide F

C37H48O10 (652.3247)

cynaphylloside A

C37H48O10 (652.3247)

1-(3-Methoxy-4-hydroxyphenyl)-1,2,3-tris(2-methoxy-4-allylphenoxy)propane

C40H44O8 (652.3036)

Thapsigargin

C34H52O12 (652.3459)

Leu Ser Glu Lys Tyr

C30H48N6O10 (652.3432)

Leu Thr Phe Gln Met

C30H48N6O8S (652.3254)

Glu Ile Arg His Val

C28H48N10O8 (652.3656)

Lys Leu Asn His Gln

C28H48N10O8 (652.3656)

C34H52O12_1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

C34H52O12 (652.3459)

Isohernandezine

C39H44N2O7 (652.3148)

Annotation level-1

Glu Arg Trp Tyr

C31H40N8O8 (652.2969)

Glu Arg Tyr Trp

C31H40N8O8 (652.2969)

Glu Trp Arg Tyr

C31H40N8O8 (652.2969)

Glu Trp Tyr Arg

C31H40N8O8 (652.2969)

Glu Tyr Arg Trp

C31H40N8O8 (652.2969)

Glu Tyr Trp Arg

C31H40N8O8 (652.2969)

Arg Glu Trp Tyr

C31H40N8O8 (652.2969)

Arg Glu Tyr Trp

C31H40N8O8 (652.2969)

Arg Trp Glu Tyr

C31H40N8O8 (652.2969)

Arg Trp Tyr Glu

C31H40N8O8 (652.2969)

Arg Tyr Glu Trp

C31H40N8O8 (652.2969)

Arg Tyr Trp Glu

C31H40N8O8 (652.2969)

Val Trp Trp Tyr

C36H40N6O6 (652.3009)

Val Trp Tyr Trp

C36H40N6O6 (652.3009)

Val Tyr Trp Trp

C36H40N6O6 (652.3009)

Trp Glu Arg Tyr

C31H40N8O8 (652.2969)

Trp Glu Tyr Arg

C31H40N8O8 (652.2969)

Trp Arg Glu Tyr

C31H40N8O8 (652.2969)

Trp Arg Tyr Glu

C31H40N8O8 (652.2969)

Trp Val Trp Tyr

C36H40N6O6 (652.3009)

Trp Val Tyr Trp

C36H40N6O6 (652.3009)

Trp Trp Val Tyr

C36H40N6O6 (652.3009)

Trp Trp Tyr Val

C36H40N6O6 (652.3009)

Trp Tyr Glu Arg

C31H40N8O8 (652.2969)

Trp Tyr Arg Glu

C31H40N8O8 (652.2969)

Trp Tyr Val Trp

C36H40N6O6 (652.3009)

Trp Tyr Trp Val

C36H40N6O6 (652.3009)

Tyr Glu Arg Trp

C31H40N8O8 (652.2969)

Tyr Glu Trp Arg

C31H40N8O8 (652.2969)

Tyr Arg Glu Trp

C31H40N8O8 (652.2969)

Tyr Arg Trp Glu

C31H40N8O8 (652.2969)

Tyr Val Trp Trp

C36H40N6O6 (652.3009)

Tyr Trp Glu Arg

C31H40N8O8 (652.2969)

Tyr Trp Arg Glu

C31H40N8O8 (652.2969)

Tyr Trp Val Trp

C36H40N6O6 (652.3009)

Tyr Trp Trp Val

C36H40N6O6 (652.3009)

KYVML

C31H52N6O7S (652.3618)

EIRHV

C28H48N10O8 (652.3656)

RDLYS

C28H44N8O10 (652.318)

PI(22:2(13Z,16Z)/0:0)

C31H57O12P (652.3587)

Uzarigenin 3-[xylosyl-(1->2)-rhamnoside]

C34H52O12 (652.3459)

1,5,16-Trihydroxy-26-oxo-6,7:22,26-diepoxyergost-24-en-3-yl hexopyranoside

C34H52O12 (652.3459)

LPI 22:2

C31H57O12P (652.3587)

PKODiA-PG

C30H53O13P (652.3224)

Aspacoside E

C34H52O12 (652.3459)

BA-delta5-3beta,7beta-diol 7betaGlcNAc,24G

C33H52N2O11 (652.3571)

Bastaxanthin C2

C38H52O7S (652.3434)

4,4-methylenebis(aniline), compound with sodium chloride (3:1)

C39H42ClN6Na (652.3057)

Boc-Gly-Lys-Arg-AMC · HCl

C29H45ClN8O7 (652.31)

Amyloid β-Protein (16-20) trifluoroacetate salt

C35H52N6O6 (652.3948)

β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of Amyloid-β (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH2 residues added at N- and C-terminal ends to aid solubility)[1].

Alvespimycin hydrochloride

C32H49ClN4O8 (652.3239)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

LANTHANUM DECANOATE

C30H57LaO6 (652.3218)

Metoprolol succinate

C34H56N2O10 (652.3935)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Metoprolol succinate is an orally active, selective β1-adrenoceptor antagonist. Metoprolol succinate shows anti-inflammation, antitumor and anti-angiogenic properties[1][2][3].

N,N-DI-P-TOLYL-N,N-BIS-(4-BUTYLPHENYL)-PHENANTHRENE-9,10-DIAMINE

C48H48N2 (652.3817)

(2S)-4-(1-benzofuran-2-ylmethyl)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide

C39H48N4O5 (652.3625)

PA(10:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C35H57O9P (652.374)

PA(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/10:0)

C35H57O9P (652.374)

PA(10:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C35H57O9P (652.374)

PA(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/10:0)

C35H57O9P (652.374)

PA(10:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C35H57O9P (652.374)

PA(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/10:0)

C35H57O9P (652.374)

PA(10:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C35H57O9P (652.374)

PA(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/10:0)

C35H57O9P (652.374)

PA(10:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C35H57O9P (652.374)

PA(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/10:0)

C35H57O9P (652.374)

2-[[(2R)-3-acetyloxy-2-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.3462)

2-[[(2R)-2-acetyloxy-3-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]-6-oxoheptanoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.3462)

2-[[(2R)-3-acetyloxy-2-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.3462)

2-[[(2R)-2-acetyloxy-3-[(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H55NO12P+ (652.3462)

Anhweidelphinine

C35H44N2O10 (652.2996)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methylbenzenesulfonamide

C35H48N4O6S (652.3294)

2-[[(2R)-2-[(E)-6-carboxy-4-hydroxyhex-5-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C31H59NO11P+ (652.3826)

(1R,14S)-9,19,20,21,25-pentamethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18(33),19,21,24,26,31-dodecaene

C39H44N2O7 (652.3148)

3,6-diamino-N-[[(8Z)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide

C25H44N14O7 (652.3517)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (13Z,16Z)-docosa-13,16-dienoate

C31H57O12P (652.3587)

Smgdg O-17:2_5:0

C31H56O12S (652.3492)

Smgdg O-16:2_6:0

C31H56O12S (652.3492)

Smgdg O-19:2_3:0

C31H56O12S (652.3492)

Smgdg O-18:2_4:0

C31H56O12S (652.3492)

Smgdg O-20:2_2:0

C31H56O12S (652.3492)

Dgdg O-14:1_2:0

C31H56O14 (652.367)

Dgdg O-13:1_3:0

C31H56O14 (652.367)

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (Z)-tridec-9-enoate

C30H52O15 (652.3306)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C30H53O13P (652.3224)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C30H53O13P (652.3224)

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C30H53O13P (652.3224)

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C30H53O13P (652.3224)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H53O10P (652.3376)

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C34H53O10P (652.3376)

1-(13Z,16Z-docosadienoyl)-glycero-3-phospho-(1-myo-inositol)

C31H57O12P (652.3587)

SMGDG O-21:3;O

C30H52O13S (652.3128)

SMGDG O-22:2

C31H56O12S (652.3492)

SQDG 21:2;O

C30H52O13S (652.3128)

SQDG 22:1

C31H56O12S (652.3492)

DGMG 16:1

C31H56O14 (652.367)

SQMG 23:1

C32H60O11S (652.3856)

DGGA 25:5;O

C34H52O12 (652.3459)

DGGA 26:4

C35H56O11 (652.3822)

PA 18:3/13:4;O2

C34H53O10P (652.3376)

PA 18:4/13:3;O2

C34H53O10P (652.3376)

PA 20:3/12:3;O

C35H57O9P (652.374)

PA 22:5/8:3;O3

C33H49O11P (652.3012)

PA 22:6/8:2;O3

C33H49O11P (652.3012)

PA 22:6/9:1;O2

C34H53O10P (652.3376)

PA 30:8;O3

C33H49O11P (652.3012)

PA 31:7;O2

C34H53O10P (652.3376)

PA 32:6;O

C35H57O9P (652.374)

PG O-18:0/7:3;O3

C31H57O12P (652.3587)

PG O-18:0/8:2;O2

C32H61O11P (652.3951)

PG O-25:3;O3

C31H57O12P (652.3587)

PG O-26:2;O2

C32H61O11P (652.3951)

PG P-18:0/7:2;O3

C31H57O12P (652.3587)

PG P-18:0/8:1;O2

C32H61O11P (652.3951)

PG 16:0/8:3;O3

C30H53O13P (652.3224)

PG 16:1/8:2;O3

C30H53O13P (652.3224)

PG 16:1/9:1;O2

C31H57O12P (652.3587)

PG 18:0/7:2;O2

C31H57O12P (652.3587)

PG 18:0/8:1;O

C32H61O11P (652.3951)

PG 20:1/5:1;O2

C31H57O12P (652.3587)

PG 20:5/7:3;O

C33H49O11P (652.3012)

PG 22:0/4:1;O

C32H61O11P (652.3951)

PG 25:2;O2

C31H57O12P (652.3587)

PG 26:1;O

C32H61O11P (652.3951)

PG 27:8;O

C33H49O11P (652.3012)

PI O-18:1/4:1

C31H57O12P (652.3587)

PI O-18:2/4:0

C31H57O12P (652.3587)

PI O-20:2/2:0

C31H57O12P (652.3587)

PI O-21:3;O

C30H53O13P (652.3224)

PI O-22:2

C31H57O12P (652.3587)

PI P-16:1/5:1;O

C30H53O13P (652.3224)

PI P-18:0/4:1

C31H57O12P (652.3587)

PI P-18:0/4:1 or PI O-18:1/4:1

C31H57O12P (652.3587)

PI P-18:1/4:0

C31H57O12P (652.3587)

PI P-18:1/4:0 or PI O-18:2/4:0

C31H57O12P (652.3587)

PI P-20:1/2:0

C31H57O12P (652.3587)

PI P-20:1/2:0 or PI O-20:2/2:0

C31H57O12P (652.3587)

PI P-22:1

C31H57O12P (652.3587)

PI P-22:1 or PI O-22:2

C31H57O12P (652.3587)

PI 17:1/4:1

C30H53O13P (652.3224)

PI 17:2/4:0

C30H53O13P (652.3224)

PI 21:2

C30H53O13P (652.3224)

PEth 30:6;O

C35H57O9P (652.374)

PM 31:6;O

C35H57O9P (652.374)

ST 27:4;O7;GlcA

C33H48O13 (652.3095)

ST 28:3;O6;GlcA

C34H52O12 (652.3459)

ST 29:2;O5;GlcA

C35H56O11 (652.3822)

ST 27:5;O8;Hex

C33H48O13 (652.3095)

ST 28:4;O7;Hex

C34H52O12 (652.3459)

ST 29:3;O6;Hex

C35H56O11 (652.3822)

CH 5450

C34H44N4O9 (652.3108)

CH 5450 (Z-Ile-Glu-Pro-Phe-Ome) is a selective short peptide human cardiac chymase inhibitor. CH-5450 inhibits the action of rat MAB elastase 2 on substrate Ang I with an IC50 value of 49 μM and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide with an IC50 value of 4.8 μM[1].

N-terminally acetylated Endomorphin-1

C36H40N6O6 (652.3009)

N-terminally acetylated Endomorphin-1 is a modified Endomorphin-1.

Z-VEID-FMK

C31H45FN4O10 (652.312)

Z-VEID-FMK (Z-VE(OMe)ID(OMe)-FMK) is a selective and irreversible caspase-6 peptide inhibitor. Z-VEID-FMK alleviates the S-(+)-ketamine-induced augmentation of caspase-6 activity, DNA fragmentation, and cell apoptosis[1][2].

n-(1-oxo-1-{[(8z,10z,16z)-3,15,24-trihydroxy-5,22-dimethoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24),21-octaen-13-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

C37H52N2O8 (652.3723)

(1s)-6-methoxy-2-methyl-1-[(4-{[(9s)-4,5,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-6-yl]oxy}phenyl)methyl]-3,4-dihydro-1h-isoquinolin-7-ol

C39H44N2O7 (652.3148)

{11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C36H48N2O9 (652.336)

2-[(6s,9s,12s,15s,18s,23as)-1,4,7,10,13,16-hexahydroxy-18-[(1r)-1-hydroxyethyl]-15-isopropyl-12-methyl-6-(2-methylpropyl)-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C29H48N8O9 (652.3544)

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e,4e,6e)-deca-2,4,6-trienoate

C37H48O10 (652.3247)

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl benzoate

C37H48O10 (652.3247)

[(2s,4r,5r,7s,9r,10s,11s,13s,14r,15s,23s,25r)-10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

C37H48O10 (652.3247)

(6r)-6-[(1s)-1-[(1s,2s,4s,5r,7s,9s,10s,11s,14r,15r,18s)-5,9-dihydroxy-10,14-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-15-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H52O12 (652.3459)

(4s)-1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl)-n-(5-carbamimidamido-1-oxopentan-2-yl)-4-methylpyrrolidine-2-carboximidic acid

C33H44N6O8 (652.322)

(1s,14r)-9,20,21,25,34-pentamethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24(32),25,27(31),35-dodecaene

C39H44N2O7 (652.3148)

(5r,6z,8r,9r,10s)-5-chloro-9-{[(2s,4r,5s,6r)-4-{[(2s,4r,5r,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-6-methyloxan-2-yl]oxy}-8-hydroxy-10-[(1z,3e,5e,7z,10z)-trideca-1,3,5,7,10-pentaen-1-yl]-3,4,5,8,9,10-hexahydrooxecin-2-one

C34H49ClO10 (652.3014)

(3s,6s,9s,12s,15s)-12-benzyl-15-[(1s)-1-hydroxyethyl]-6-[(4-hydroxyphenyl)methyl]-3-methyl-9-(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C33H44N6O8 (652.322)

(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl (1r,2r,4as,6as,6br,8ar,9r,10r,11r,12s,12ar,12bs,14bs)-1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822)

6-methoxy-2-methyl-1-{[4-({4,5,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2,4,6,13(17),14-hexaen-6-yl}oxy)phenyl]methyl}-3,4-dihydro-1h-isoquinolin-7-ol

C39H44N2O7 (652.3148)

6,19,20,21,25-pentamethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.2⁹,¹².1³,⁷.1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,7(36),9,11,18(33),19,21,24(32),25,27(31),34-dodecaene

C39H44N2O7 (652.3148)

(1s,5r,7e,9r,10r,11r,12r,13s)-5-[(1e,3e)-6-[(1s,2r)-2-chlorocyclopropyl]hexa-1,3-dien-5-yn-1-yl]-13-{[(2s,3r,4r,5s,6r)-4,5-dihydroxy-3-methoxy-4,6-dimethyloxan-2-yl]oxy}-1-hydroxy-9-methoxy-7,10,12-trimethyl-4,15-dioxabicyclo[9.3.1]pentadec-7-en-3-one

C34H49ClO10 (652.3014)

3,4,5-trihydroxyoxan-2-yl 1,10,11,12-tetrahydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C35H56O11 (652.3822)

(2s)-2-({[(2s)-1-[(2s)-2-({[(2s)-1-[(2s)-2-{[(2s)-2-amino-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-3-methylbutanoyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

C31H52N6O9 (652.3796)

4-[(6-methoxy-2-methyl-7-{[(1s,9s)-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-2(7),3,5,10(15),11,13-hexaen-6-yl]oxy}-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenol

C39H44N2O7 (652.3148)

12β,21-dihydroxycimigenol3-o-α-l-arabinopyranoside

C35H56O11 (652.3822)

{"Ingredient_id": "HBIN000742","Ingredient_name": "12\u03b2,21-dihydroxycimigenol3-o-\u03b1-l-arabinopyranoside","Alias": "NA","Ingredient_formula": "C35H56O11","Ingredient_Smile": "CC1(C2CCC3C4(C(C56C(C4(C(CC37C2(C7)CCC1OC8C(C(C(CO8)O)O)O)O)C)C(CC(O5)C(O6)C(C)(C)O)CO)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5789","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

2α, 3β, 23-trihydroxyurs-5, 12-dien-28-oic acid

C35H56O11 (652.3822)

{"Ingredient_id": "HBIN005214","Ingredient_name": "2\u03b1, 3\u03b2, 23-trihydroxyurs-5, 12-dien-28-oic acid","Alias": "NA","Ingredient_formula": "C35H56O11","Ingredient_Smile": "CC1(C2CCC3C4(C(C56C(C4(C(CC37C2(C7)CCC1OC8C(C(C(CO8)O)O)O)O)C)C(CC(O5)C(O6)C(C)(C)O)CO)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42093","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

12-benzyl-15-(1-hydroxyethyl)-6-[(4-hydroxyphenyl)methyl]-3-methyl-9-(2-methylpropyl)-1,4,7,10,13,16-hexaazacyclooctadeca-1,4,7,10,13,16-hexaene-2,5,8,11,14,17-hexol

C33H44N6O8 (652.322)

2-[(6s,9s,12s,15s,18s,23as)-6-[(2s)-butan-2-yl]-1,4,7,10,13,16-hexahydroxy-18-[(1r)-1-hydroxyethyl]-15-isopropyl-12-methyl-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C29H48N8O9 (652.3544)

6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl deca-2,4,6-trienoate

C37H48O10 (652.3247)

4-[(1r)-1-[(9s,10s,14s)-3,14-dihydroxy-7,7,11,11,13,13-hexamethyl-4-(2-methylpropanoyl)-12-oxo-6,15-dioxatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁴]hexadeca-1,3,5(16)-trien-2-yl]-2-methylpropyl]-5-hydroxy-2,2,6,6-tetramethylcyclohex-4-ene-1,3-dione

C38H52O9 (652.3611)

(2r,3s,8s,13r,14s,19r)-8-butyl-19-(4,4-dichlorobutyl)-3,14-dimethyltricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-2,10,13,21,24,26-hexol

C36H54Cl2O6 (652.3297)

(1r,14s)-9,20,21,25,34-pentamethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24(32),25,27(31),35-dodecaene

C39H44N2O7 (652.3148)

(2r,4r,8s,13r,15r,19s)-8,19-dibutyl-4,15-dichloro-2,13-dimethoxytricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-10,21,24,26-tetrol

C36H54Cl2O6 (652.3297)

(6s,6ar,10as,14r)-7,10a,13-trihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6,6a,7,14-tetrahydro-5,11-dioxapentaphene-1,3,9-trione

C38H52O9 (652.3611)

2-[1,4,7,10,13,16-hexahydroxy-18-(1-hydroxyethyl)-15-isopropyl-12-methyl-6-(2-methylpropyl)-19-oxo-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-9-yl]ethanimidic acid

C29H48N8O9 (652.3544)

4-{[(1s)-6-methoxy-2-methyl-7-{[(1s,9s)-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-2(7),3,5,10(15),11,13-hexaen-6-yl]oxy}-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol

C39H44N2O7 (652.3148)

2-{[2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

C35H56O11 (652.3822)

[(1r,2r,4r,5r,6s,7s,9r,10s,11s,13s,14r,15r,23s,25r)-10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

C37H48O10 (652.3247)

{8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-11-en-13-yl}methyl 2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate

C35H44N2O10 (652.2996)

9,19,20,21,25-pentamethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaene

C39H44N2O7 (652.3148)

[(1s,2r,3r,4s,5s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C36H48N2O9 (652.336)

8-butyl-19-(4,4-dichlorobutyl)-3,14-dimethyltricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-2,10,13,21,24,26-hexol

C36H54Cl2O6 (652.3297)

6-[1-(5,9-dihydroxy-10,14-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-15-yl)ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H52O12 (652.3459)

4-[(1s)-1-{2,4-dihydroxy-5-[(1r)-1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]-3-(2-methylpropanoyl)phenyl}-2-methylpropyl]-5-hydroxy-2,2,6,6-tetramethylcyclohex-4-ene-1,3-dione

C38H52O9 (652.3611)

(1s,9s)-5,12,13-trimethoxy-14-{[(1s)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl]oxy}-17-methyl-17-azatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadeca-2,4,6,10,12,14-hexaen-4-ol

C39H44N2O7 (652.3148)

(2r,3s)-3-[(1r,3as,3bs,4r,9ar,9bs,11ar)-9a,11a-dimethyl-7-oxo-4-(pyridine-3-carbonyloxy)-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-[(2s)-2,3,3-trimethyloxiran-2-yl]butan-2-yl pyridine-3-carboxylate

C40H48N2O6 (652.3512)

(3s,3ar,4s,6s,6ar,7s,8s,9bs)-6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-8-{[(1s,2z)-1-hydroxy-2-methylbut-2-en-1-yl]oxy}-3,6,9-trimethyl-2-oxo-4h,5h,6ah,7h,8h,9bh-azuleno[4,5-b]furan-7-yl octanoate

C34H52O12 (652.3459)

(5e,21z,31e)-12,25,28,30,35-pentahydroxy-6,22,32-trimethyl-9-(prop-1-en-2-yl)pentacyclo[16.15.1.1¹⁰,¹⁴.0²,¹⁶.0²⁴,²⁹]pentatriaconta-5,10(35),11,13,18(34),21,24,26,28,31-decaene-2-carbaldehyde

C42H52O6 (652.3764)

(3s,22s)-10,11,15,16,27-pentamethoxy-4,21-dimethyl-13,29-dioxa-4,21-diazaheptacyclo[28.2.2.1¹⁴,¹⁸.1²⁴,²⁸.0³,⁸.0⁷,¹².0²²,³⁶]hexatriaconta-1(32),7(12),8,10,14,16,18(36),24,26,28(35),30,33-dodecaene

C39H44N2O7 (652.3148)

(1s)-6,7-dimethoxy-1-{[4-methoxy-3-(4-{[(5s)-9-methoxy-6-methyl-2h,5h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]methyl}phenoxy)phenyl]methyl}-2-methyl-3,4-dihydro-1h-isoquinoline

C39H44N2O7 (652.3148)

2-methoxy-4-{1,2,3-tris[2-methoxy-4-(prop-2-en-1-yl)phenoxy]propyl}phenol

C40H44O8 (652.3036)

n-[(2r)-1-oxo-1-{[(6z,8z,10z,16z)-3,15,24-trihydroxy-5-methoxy-14,16-dimethyl-21,22-dioxo-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24)-heptaen-13-yl]oxy}propan-2-yl]cyclohexanecarboximidic acid

C36H48N2O9 (652.336)

(1s,14s)-6,19,20,21,25-pentamethoxy-15,30-dimethyl-8,23-dioxa-15,30-diazaheptacyclo[22.6.2.2⁹,¹².1³,⁷.1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,7(36),9,11,18(33),19,21,24(32),25,27(31),34-dodecaene

C39H44N2O7 (652.3148)

6-(acetyloxy)-4-(butanoyloxy)-3,3a-dihydroxy-8-[(1-hydroxy-2-methylbut-2-en-1-yl)oxy]-3,6,9-trimethyl-2-oxo-4h,5h,6ah,7h,8h,9bh-azuleno[4,5-b]furan-7-yl octanoate

C34H52O12 (652.3459)

2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)

(2s,3e,6r,7r,10e,14r,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)

(1r,14s)-9,19,20,21,25-pentamethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.2³,⁶.1⁸,¹².1¹⁴,¹⁸.0²⁷,³¹.0²²,³³]hexatriaconta-3,5,8(34),9,11,18(33),19,21,24,26,31,35-dodecaene

C39H44N2O7 (652.3148)

n-(1-oxo-1-{[(8e,10e,16z)-3,13,24-trihydroxy-5-methoxy-14,16-dimethyl-21,22-dioxo-2-azabicyclo[18.3.1]tetracosa-1(23),2,6,8,10,16,20(24)-heptaen-15-yl]oxy}propan-2-yl)cyclohexanecarboximidic acid

C36H48N2O9 (652.336)

(1r,3as,9as,11as)-2,8-dihydroxy-1-[(2r)-2-hydroxy-6-methyl-3-oxoheptan-2-yl]-3a,6,6,11a-tetramethyl-7-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,7h,8h,9h,9ah,9bh,11h-cyclopenta[a]phenanthren-10-one

C35H56O11 (652.3822)

5-chloro-9-({4-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-5-hydroxy-6-methyloxan-2-yl}oxy)-8-hydroxy-10-[(3e,5e)-trideca-1,3,5,7,10-pentaen-1-yl]-3,4,5,8,9,10-hexahydrooxecin-2-one

C34H49ClO10 (652.3014)

2-({[1-(2-{[(1-{2-[(2-amino-1-hydroxy-3-methylbutylidene)amino]-4-methylpentanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-3-methylbutanoyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)pentanedioic acid

C31H52N6O9 (652.3796)

(1r,2r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-19-(acetyloxy)-8-(furan-3-yl)-1,9,11,16-tetramethyl-17-[(2-methylpropanoyl)oxy]-4-oxo-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C37H48O10 (652.3247)

3-[9a,11a-dimethyl-7-oxo-4-(pyridine-3-carbonyloxy)-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-(2,3,3-trimethyloxiran-2-yl)butan-2-yl pyridine-3-carboxylate

C40H48N2O6 (652.3512)

8,19-dibutyl-4,15-dichloro-2,13-dimethoxytricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-10,21,24,26-tetrol

C36H54Cl2O6 (652.3297)

19-(acetyloxy)-8-(furan-3-yl)-1,9,11,16-tetramethyl-17-[(2-methylpropanoyl)oxy]-4-oxo-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C37H48O10 (652.3247)

[(1r,2s,4r,5r,6s,7s,9r,10s,11s,13s,14s,15r,25r)-10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

C37H48O10 (652.3247)

[10,11-dihydroxy-9-(hydroxymethyl)-13,15-dimethyl-12-oxo-4-(prop-1-en-2-yl)-8,24,26,27-tetraoxaheptacyclo[12.10.1.1⁴,²³.1⁵,²³.0¹,⁶.0⁷,⁹.0¹¹,²⁵]heptacosan-2-yl]methyl benzoate

C37H48O10 (652.3247)

(1r,2r,4s,5s,6s,7s,8r,9s,10s,11r,13s,15r,17r)-6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-5-yl (2e,4e,6e)-deca-2,4,6-trienoate

C37H48O10 (652.3247)

(2s,3r,4r,5r,6r)-2-{[(2r,3r,4r,6r)-6-{[(2s,3s,6s,8s,11r,14r,17r,18s,19s)-19-hydroxy-3,13,18-trimethyl-12,20-dioxahexacyclo[11.6.1.0²,¹¹.0³,⁸.0¹¹,¹⁷.0¹⁴,¹⁸]icosan-6-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C35H56O11 (652.3822)

(2s,3e,6s,7s,10e,14r,21s,26z)-2,17,31,33,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)

(2s,3r,4s,5s)-2-{[(1s,2r,3s,4r,7r,9s,12r,14r,16r,17r,18r,19r,21r,22s)-2,16-dihydroxy-19-(hydroxymethyl)-22-(2-hydroxypropan-2-yl)-3,8,8,17-tetramethyl-23,24-dioxaheptacyclo[19.2.1.0¹,¹⁸.0³,¹⁷.0⁴,¹⁴.0⁷,¹².0¹²,¹⁴]tetracosan-9-yl]oxy}oxane-3,4,5-triol

C35H56O11 (652.3822)

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadec-11-en-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate

C35H44N2O10 (652.2996)

[5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl deca-2,4,6-trienoate

C37H48O10 (652.3247)

(2s,3e,6r,7s,10e,14s,21s,26z)-2,17,30,32,35-pentahydroxy-4,11,27-trimethyl-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(31),3,10,15(35),16,18,23(34),26,29,32-decaene-7-carbaldehyde

C42H52O6 (652.3764)

2-methoxy-4-[(1s,2s)-1,2,3-tris[2-methoxy-4-(prop-2-en-1-yl)phenoxy]propyl]phenol

C40H44O8 (652.3036)

(1r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-14-nonyl-5-oxo-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl benzoate

C37H48O10 (652.3247)